Ad Combination Therapy Matrix is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task: rs003 | Last Updated: 2026-03-05 | Matrix Size: 15×15 (105 unique combinations)
Single-target approaches have all shown modest benefit in Alzheimer's disease — the best result (lecanemab) shows only 27% slowing of cognitive decline. This suggests that combination therapy targeting multiple mechanisms simultaneously may be necessary for disease modification.
This page scores every pairwise combination of the top 15 therapeutic approaches from the AD Therapeutic Scorecard (rs001) across four dimensions:
| # | Approach | rs001 Score |
|---|---|---|
| 1 | Lifestyle interventions (exercise, diet, sleep) | 61 |
| 2 | Anti-amyloid antibodies (Lecanemab, Donanemab) | 55 |
| 3 | GLP-1 agonists (Semaglutide) | 55 |
| 4 | Anti-tau antibodies (E2814, Bepranemab) | 52 |
| 5 | Anti-tau ASOs (BIIB080) | 51 |
| 6 | Intranasal insulin | 50 |
| 7 | TREM2 agonists (AL002) | 49 |
| 8 | Focused ultrasound + drug delivery | 49 |
| 9 | Mitochondrial therapies (NAD+ boosters) | 47 |
| 10 | Anti-inflammatory (Masitinib) | 46 |
| 11 | Senolytics (Dasatinib + Quercetin) | 45 |
| 12 | HDAC inhibitors | 41 |
| 13 | Sigma-1 agonists (Blarcamesine) | 41 |
| 14 | Glutamate modulators (Troriluzole) | 38 |
| 15 | Gene therapy (AAV-BDNF, AAV-NGF) | 38 |
| 1.Lifestyle | 2.Anti-Aβ | 3.GLP-1 | 4.Anti-Tau Ab | 5.Anti-Tau ASO | 6.InsuLIN | 7.TREM2 | 8.FUS | 9.Mito | 10.Anti-Infl | 11.Senolytic | 12.HDAC | 13.σ1 | 14 Glut | 15.GT | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.Lifestyle | — | ||||||||||||||
| 2.Anti-Aβ | 10/10/10/8=38 | — | |||||||||||||
| 3.GLP-1 | 10/10/10/7=37 | 8/9/9/7=33 | — | ||||||||||||
| 4.Anti-Tau Ab | 9/9/8/6=32 | 9/7/8/8=32 | 8/8/8/5=29 | — | |||||||||||
| 5.Anti-Tau ASO | 9/8/6/5=28 | 9/7/6/7=29 | 8/8/6/4=26 | 8/7/6/7=28 | — | ||||||||||
| 6.Intranasal Ins | 9/9/9/6=33 | 7/8/8/5=28 | 8/9/8/5=30 | 7/7/7/4=25 | 7/7/6/4=24 | — | |||||||||
| 7.TREM2 Ag | 8/8/7/5=28 | 8/6/7/5=26 | 8/7/7/4=26 | 8/6/7/5=26 | 8/6/6/4=24 | 7/7/7/4=25 | — | ||||||||
| 8.FUS | 8/9/6/5=28 | 7/7/7/7=28 | 7/8/6/5=26 | 7/7/6/5=25 | 7/7/6/5=25 | 7/8/6/4=25 | 7/6/6/4=23 | — | |||||||
| 9.Mito | 9/9/8/5=31 | 7/7/7/4=25 | 8/8/7/5=28 | 7/7/6/4=24 | 7/7/6/4=24 | 8/8/7/4=27 | 7/7/6/4=24 | 6/7/5/4=22 | — | ||||||
| 10. 8/9/8/5Anti-Infl | =30 | 6/6/7/5=24 | 8/8/7/5=28 | 7/6/6/4=23 | 7/6/6/4=23 | 7/7/7/4=25 | 7/6/6/4=23 | 7/6/5/4=22 | 8/8/7/5=28 | — | |||||
| 11.Senolytic | 8/8/7/5=28 | 7/6/6/4=23 | 8/7/6/4=25 | 7/6/5/4=22 | 7/6/5/4=22 | 7/7/6/4=24 | 7/6/5/4=22 | 6/6/5/4=21 | 8/7/6/5=26 | 7/6/6/5=24 | — | ||||
| 12.HDAC | 8/8/6/4=26 | 6/6/6/4=22 | 7/7/6/4=24 | 7/6/5/4=22 | 7/6/5/4=22 | 7/7/6/4=24 | 7/6/5/4=22 | 6/6/5/4=21 | 7/7/6/4=24 | 7/6/6/4=23 | 7/6/5/4=22 | — | |||
| 13.σ1 Agonist | 8/8/7/4=27 | 6/7/6/4=23 | 7/7/6/4=24 | 6/6/5/4=21 | 6/6/5/4=21 | 7/7/6/4=24 | 6/6/5/4=21 | 6/6/5/4=21 | 7/7/6/4=24 | 7/6/6/4=23 | 6/6/5/4=21 | 6/6/5/4=21 | — | ||
| 14.Glutamate | 7/8/6/4=25 | 6/6/6/4=22 | 7/7/6/4=24 | 6/5/5/4=20 | 6/5/5/4=20 | 7/7/6/4=24 | 6/5/5/4=20 | 6/5/5/4=20 | 6/6/5/4=21 | 6/5/5/4=20 | 6/5/5/4=20 | 6/5/5/4=20 | 6/5/5/4=20 | — | |
| 15.Gene Tx | 7/6/4/4=21 | 6/5/4/5=20 | 6/5/4/4=19 | 6/5/4/5=20 | 6/5/4/5=20 | 6/5/4/4=19 | 6/5/4/4=19 | 5/5/4/4=18 | 6/5/4/4=19 | 6/5/4/4=19 | 5/5/4/4=18 | 5/5/4/4=18 | 5/5/4/4=18 | 5/5/4/4=18 | — |
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Synergy | 10 | Lifestyle addresses upstream risk factors; anti-amyloid removes existing plaques — complementary |
| Safety Compatibility | 10 | No drug-drug interaction; lifestyle has zero adverse events |
| Delivery Compatibility | 10 | Lifestyle requires no delivery; anti-amyloid is IV infusion — completely separate |
| Evidence | 8 | FINGER trial shows lifestyle intervention + standard of care works; no direct combo trials yet |
Clinical Rationale: The FINGER trial showed lifestyle intervention benefits even in at-risk elderly. Combining with lecanemab could address both existing pathology (plaques) and upstream modifiable risk factors.
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Synergy | 8 | Anti-amyloid removes Aβ; GLP-1 addresses neuroinflammation and metabolic dysfunction — different pathways |
| Safety Compatibility | 9 | Both have good safety profiles; GLP-1 has GI side effects but not overlapping with ARIA |
| Delivery Compatibility | 9 | Both injectable (IV monthly + weekly subcutaneous) — manageable |
| Evidence | 7 | EVOKE/EVOKE+ trials ongoing for semaglutide in AD; preclinical shows synergy |
Clinical Rationale: Lecanemab removes plaques; GLP-1 agonists protect neurons from inflammation and metabolic stress. Different mechanisms could produce additive or synergistic effects.
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Synergy | 10 | Both address metabolic/inflammatory pathways from different angles |
| Safety Compatibility | 10 | Both extremely safe — lifestyle has no drugs; GLP-1 has well-characterized safety |
| Delivery Compatibility | 10 | Lifestyle = behavior; GLP-1 = weekly injection — separate modalities |
| Evidence | 7 | FINGER trial for lifestyle; EVOKE trials for GLP-1; no direct combo trials |
Clinical Rationale: Maximum safety profile combined. Both address metabolic dysfunction which is a key AD risk factor. Easy to implement.
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Synergy | 9 | Insulin improves neuronal metabolism; lifestyle improves overall health — complementary |
| Safety Compatibility | 9 | Intranasal insulin has minimal systemic absorption; lifestyle is non-pharmacological |
| Delivery Compatibility | 9 | Intranasal = daily nasal spray; lifestyle = behavioral — separate |
| Evidence | 6 | Intranasal insulin trials (SNIFF) show mixed results; no combo trials |
Clinical Rationale: Intranasal insulin directly improves brain glucose metabolism. Combined with lifestyle could address both central and peripheral metabolic dysfunction.
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Synergy | 9 | Different targets — Aβ plaques vs tau tangles; both extracellular |
| Safety Compatibility | 7 | Both can cause ARIA, though tau antibodies have lower risk |
| Delivery Compatibility | 8 | Both IV infusions — could be coordinated |
| Evidence | 8 | Trials planning this combination; strong mechanistic rationale |
Clinical Rationale: The "dual attack" strategy — remove plaques AND tangles. Both are hallmarks of AD pathology. This combination is in clinical trial planning.
Lifestyle is the universal partner: Every combination involving lifestyle scores highest because it adds no toxicity and no delivery complexity.
Anti-amyloid + GLP-1 is the top drug-drug combo: Different mechanisms (plaque removal + neuroinflammation) with good safety overlap.
Anti-amyloid + anti-tau has strongest clinical interest: Both target distinct pathological hallmarks. Trials planning this combination.
Gene therapy combinations score lowest: Delivery complexity and safety concerns limit combinability.
Anti-inflammatory combinations are under-explored: Despite known neuroinflammation role, anti-inflammatory combinations score mid-range — opportunity for research.
The study of Ad Combination Therapy Matrix has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 7 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 32%